MNPR Triangle 2.JPG
Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference
08 mars 2022 08h00 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
mono.jpg
Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic WILMETTE, Ill. and BELOIT, Wis., May 26, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional...
monopar.jpg
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
11 févr. 2021 07h30 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
monopar.jpg
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada
09 févr. 2021 07h00 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...